Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The risk of venous thromboembolism in kidney transplant recipients is enhanced following a cytomegalovirus infection.

Frontiers in immunology·2026

Same author

Qualified prediction system for allograft failure in real world settings: extended validation study.

BMJ medicine·2026

Same author

Corrigendum to "Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: A multicenter international study" [American Journal of Transplantation 25 (2025) 1631-1642].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

Same author

A Prediction Model for Risk of Death in Kidney Transplant Recipients.

JAMA network open·2026

Same author

Impaired thymic function is independently associated with an increased risk of posttransplant infections in kidney recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

Same author

Genetic screening in kidney transplant candidates.

Clinical kidney journal·2026

Same journal

Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.

Clinical transplants·2017

Same journal

Influenza Immunization and the Generation of Anti-HLA and Anti-MICA Antibodies in Patients with Renal Failure and in Kidney Transplant Recipients.

Clinical transplants·2017

Same journal

From Accurate Assessment of Anti-HLA Antibody MFI to Complement-Binding Assays.

Clinical transplants·2017

Same journal

Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.

Clinical transplants·2017

Same journal

Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD).

Clinical transplants·2017

Same journal

C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.

Clinical transplants·2017

See all related articles

Search research articles

Related Experiment Video

Updated: May 31, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.

Rebecca Sberro-Soussan¹, Julien Zuberl, Caroline Suberbielle-Boissel

¹Service de Transplantation Rénale, Hôpital Necker, Paris, France.

Clinical Transplants

|June 24, 2011

Summary

This summary is machine-generated.

Bortezomib therapy did not reduce donor-specific antibodies (DSA) in kidney transplant recipients with antibody-mediated rejection. Long-term follow-up confirmed stable or increased DSA levels, indicating limited efficacy for this treatment approach.

More Related Videos

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Related Experiment Videos

Last Updated: May 31, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Area of Science:

Nephrology
Immunology
Transplantation

Background:

Sub-acute antibody-mediated rejection (AMR) in renal transplant recipients often involves persistent donor-specific antibodies (DSA).
Bortezomib has been investigated as a desensitization therapy to manage AMR and reduce DSA levels.

Observation:

A previous study evaluated one cycle of Bortezomib in four renal transplant recipients with sub-acute AMR and persistent DSA.
DSA levels, measured by mean fluorescence intensity (MFI), did not significantly decrease within 270 days post-treatment.

Findings:

Reevaluation after one year showed that DSA levels remained stable or increased in all patients.
One cycle of Bortezomib as a sole desensitization therapy was ineffective in decreasing DSA levels in sensitized kidney transplant recipients.

Implications:

Bortezomib monotherapy may not be sufficient for managing persistent DSA in kidney transplant recipients with AMR.
Further research is needed to explore alternative or combination therapies for effective DSA reduction and improved transplant outcomes.